Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA).

Di Cara B, Maggio R, Aloisi G, Rivet JM, Lundius EG, Yoshitake T, Svenningsson P, Brocco M, Gobert A, De Groote L, Cistarelli L, Veiga S, De Montrion C, Rodriguez M, Galizzi JP, Lockhart BP, Cogé F, Boutin JA, Vayer P, Verdouw PM, Groenink L, Millan MJ.

J Neurosci. 2011 Nov 23;31(47):16928-40. doi: 10.1523/JNEUROSCI.2502-11.2011.

2.

Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour.

Orejarena MJ, Lanfumey L, Maldonado R, Robledo P.

Int J Neuropsychopharmacol. 2011 Aug;14(7):927-40. doi: 10.1017/S1461145710001215. Epub 2010 Oct 14.

PMID:
20942998
3.

Normal thermoregulatory responses to 3-iodothyronamine, trace amines and amphetamine-like psychostimulants in trace amine associated receptor 1 knockout mice.

Panas HN, Lynch LJ, Vallender EJ, Xie Z, Chen GL, Lynn SK, Scanlan TS, Miller GM.

J Neurosci Res. 2010 Jul;88(9):1962-9. doi: 10.1002/jnr.22367.

4.
5.

Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice.

Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA.

Neuropsychopharmacology. 2006 Nov;31(11):2349-58. Epub 2006 Jul 19.

6.

Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain.

Baumann MH, Clark RD, Rothman RB.

Pharmacol Biochem Behav. 2008 Aug;90(2):208-17. doi: 10.1016/j.pbb.2008.02.018. Epub 2008 Mar 4.

7.
8.

Long-term neurobiological consequences of ecstasy: a role for pre-existing trait-like differences in brain monoaminergic functioning?

Wallinga AE, de Boer SF, Granneman RA, Koolhaas JM, Buwalda B.

Pharmacol Biochem Behav. 2009 Dec;94(2):227-33. doi: 10.1016/j.pbb.2009.08.009. Epub 2009 Aug 21.

PMID:
19699758
9.

3,4-methylenedioxymethamphetamine self-administration is abolished in serotonin transporter knockout mice.

Trigo JM, Renoir T, Lanfumey L, Hamon M, Lesch KP, Robledo P, Maldonado R.

Biol Psychiatry. 2007 Sep 15;62(6):669-79. Epub 2007 Feb 16.

PMID:
17306775
10.

N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').

Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB.

Neuropsychopharmacology. 2005 Mar;30(3):550-60.

11.

The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system.

White SR, Obradovic T, Imel KM, Wheaton MJ.

Prog Neurobiol. 1996 Aug;49(5):455-79. Review.

PMID:
8895996
13.

Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain.

Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB.

Ann N Y Acad Sci. 2004 Oct;1025:189-97.

PMID:
15542717
14.

Studies on the effect of MDMA ('ecstasy') on the body temperature of rats housed at different ambient room temperatures.

Green AR, O'Shea E, Saadat KS, Elliott JM, Colado MI.

Br J Pharmacol. 2005 Sep;146(2):306-12.

15.

Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse.

Fantegrossi WE, Kiessel CL, De la Garza R 2nd, Woods JH.

Psychopharmacology (Berl). 2005 Sep;181(3):529-36. Epub 2005 Oct 12.

17.

Risperidone attenuates and reverses hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.

Shioda K, Nisijima K, Yoshino T, Kuboshima K, Iwamura T, Yui K, Kato S.

Neurotoxicology. 2008 Nov;29(6):1030-6. doi: 10.1016/j.neuro.2008.07.005. Epub 2008 Aug 5.

PMID:
18722468
18.
19.

Electrophysiologic changes in ventral midbrain dopaminergic neurons resulting from (+/-) -3,4-methylenedioxymethamphetamine (MDMA-"Ecstasy").

Federici M, Sebastianelli L, Natoli S, Bernardi G, Mercuri NB.

Biol Psychiatry. 2007 Sep 15;62(6):680-6. Epub 2007 May 23.

PMID:
17511969
20.

Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A2A receptor antagonist in mice: A potential role of GPR52 in the function of striatopallidal neurons.

Nishiyama K, Suzuki H, Maruyama M, Yoshihara T, Ohta H.

Brain Res. 2017 Sep 1;1670:24-31. doi: 10.1016/j.brainres.2017.05.031. Epub 2017 Jun 3.

PMID:
28583861

Supplemental Content

Support Center